 ValuEngine downgraded shares of IGM Biosciences NASDAQ:IGMS from a buy rating to a hold rating in a report released on Thursday, ValuEngine reports. A number of other analysts have also recently issued reports on the stock. Stifel Nicolaus lifted their target price on shares of IGM Biosciences from 67.00 to 95.00 and gave the company ... 